IL6 and congenital rubella syndrome: Recent preclinical evidence suggests that in ex vivo CRS assays and in vivo murine models of CD19 CART, the dual PI3K-δ and -γ inhibitor duvelisib, antagonizes and reduces IL-6 secretion better than single agent isoform selective PI3K-δ and -γ inhibitors without negatively inhibiting CART function (232).